Humanized anti-C5 antibodies and uses thereof
US12098190B2 · kind B2 · utility
0Cited by
4References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 6, 2019 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Oct 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.